<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.herpesviridae.org/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Herpesviridae - Most accessed articles</title>
        <link>http://www.herpesviridae.org</link>
        <description>The most accessed research articles published by Herpesviridae</description>
        <dc:date>2012-03-26T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/2/1/3" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/2/1/6" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/2/1/1" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/3/1/4" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/2/1/7" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/1/1/8" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/1/1/6" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/2/1/8" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/3/1/1" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/2/1/10" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.herpesviridae.org/content/2/1/3">
        <title>Tegument Protein Control of Latent Herpesvirus Establishment and Animation</title>
        <description>Herpesviruses are successful pathogens that infect most vertebrates as well as at least one invertebrate species. Six of the eight human herpesviruses are widely distributed in the population. Herpesviral infections persist for the life of the infected host due in large part to the ability of these viruses to enter a non-productive, latent state in which viral gene expression is limited and immune detection and clearance is avoided. Periodically, the virus will reactivate and enter the lytic cycle, producing progeny virus that can spread within or to new hosts. Latency has been classically divided into establishment, maintenance, and reactivation phases. Here we focus on demonstrated and postulated molecular mechanisms leading to the establishment of latency for representative members of each human herpesvirus family. Maintenance and reactivation are also briefly discussed. In particular, the roles that tegument proteins may play during latency are highlighted. Finally, we introduce the term animation to describe the initiation of lytic phase gene expression from a latent herpesvirus genome, and discuss why this step should be separated, both molecularly and theoretically, from reactivation.</description>
        <link>http://www.herpesviridae.org/content/2/1/3</link>
                <dc:creator>Rhiannon Penkert</dc:creator>
                <dc:creator>Robert Kalejta</dc:creator>
                <dc:source>Herpesviridae 2011, null:3</dc:source>
        <dc:date>2011-02-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-2-3</dc:identifier>
                                <prism:require>/content/figures/2042-4280-2-3-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2011-02-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/2/1/6">
        <title>Cytomegalovirus-induced immunopathology and its clinical consequences</title>
        <description>Human cytomegalovirus (CMV) is a ubiquitous DNA virus that causes severe disease in patients with immature or impaired immune systems. During active infection, CMV modulates host immunity, and CMV-infected patients often develop signs of immune dysfunction, such as immunosuppression and autoimmune phenomena. Furthermore, active viral infection has been observed in several autoimmune diseases, and case reports have linked primary CMV infection and the onset of autoimmune disorders. In addition, CMV infection promotes allograft rejection and graft-versus-host disease in solid organ and bone marrow transplant recipients, respectively, further implicating CMV in the genesis and maintenance of immunopathological phenomena. The mechanisms by which CMV could induce inhibition of host defense, inflammation, and autoimmunity are discussed, as is the treatment of virus-induced immunopathology with antivirals.</description>
        <link>http://www.herpesviridae.org/content/2/1/6</link>
                <dc:creator>Stefania Varani</dc:creator>
                <dc:creator>Maria Landini</dc:creator>
                <dc:source>Herpesviridae 2011, null:6</dc:source>
        <dc:date>2011-04-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-2-6</dc:identifier>
                                <prism:require>/content/figures/2042-4280-2-6-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2011-04-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/2/1/1">
        <title>Innate immune modulation in EBV infection</title>
        <description>Epstein-Barr Virus (EBV) belongs to the gammaherpesvirus family, members of which are oncogenic. Compared with other closely related herpesviruses, EBV has developed much more elaborate and sophisticated strategies for subverting host immune system, which may account for its high prevalence in immune competent hosts. Thus, study of EBV-specific immune dysregulation is important for understanding EBV latency and oncogenesis, and will identify potential molecular targets for immunotherapeutic interventions. Here I summarize the recent findings of individual EBV products in regulating host immune responses, with emphasis on the innate immune modulation.</description>
        <link>http://www.herpesviridae.org/content/2/1/1</link>
                <dc:creator>Shunbin Ning</dc:creator>
                <dc:source>Herpesviridae 2011, null:1</dc:source>
        <dc:date>2011-01-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-2-1</dc:identifier>
                                <prism:require>/content/figures/2042-4280-2-1-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2011-01-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/3/1/4">
        <title>The effect of mouse strain on herpes simplex virus type 1 (HSV-1) infection of the central nervous system (CNS)</title>
        <description>Background:
Mice infected with HSV-1 can develop lethal encephalitis or virus induced CNS demyelination. Multiple factors affect outcome including route of infection, virus and mouse strain. When infected with a sub-lethal dose of HSV-1 strain 2 via the oral mucosa, susceptible SJL/J, A/J, and PL/J mice develop demyelinating lesions throughout the brain. In contrast, lesions are restricted to the brainstem (BST) in moderately resistant BALB/c mice and are absent in resistant BL/6 mice. The reasons for the strain differences are unknown.
Methods:
In this study, we combine histology, immunohistochemistry, and in-situ hybridization to investigate the relationship between virus and the development of lesions during the early stage (&lt; 24 days PI) of demyelination in different strains of mice.
Results:
Initially, viral DNA and antigen positive cells appear sequentially in non-contiguous areas throughout the brains of BALB/c, SJL/J, A/J, and PL/J mice but are restricted to an area of the BST of BL/6 mice. In SJL/J, A/J, and PL/J mice, this is followed by the development of &apos;focal&apos; areas of virus infected neuronal and non-neuronal cells throughout the brain. The &apos;focal&apos; areas follow a hierarchical order and co-localize with developing demyelinating lesions. When antigen is cleared, viral DNA positive cells can remain in areas of demyelination; consistent with a latent infection. In contrast, &apos;focal&apos; areas are restricted to the BST of BALB/c mice and do not occur in BL/6 mice.
Conclusions:
The results of this study indicate that susceptible mouse strains, infected with HSV-1 via the oral mucosa, develop CNS demyelination during the first 24 days PI in several stages. These include: the initial spread of virus and infection of cells in non-contiguous areas throughout the brain, the development of &apos;focal&apos; areas of virus infected neuronal and non-neuronal cells, the co-localization of &apos;focal&apos; areas with developing demyelinating lesions, and latent infection in a number of the lesions. In contrast, the limited demyelination that develops in BALB/c and the lack of demyelination in BL/6 mice correlates with the limited or lack of &apos;focal&apos; areas of virus infected neuronal and non-neuronal cells in these two strains.</description>
        <link>http://www.herpesviridae.org/content/3/1/4</link>
                <dc:creator>Lorne Kastrukoff</dc:creator>
                <dc:creator>Allen Lau</dc:creator>
                <dc:creator>Eva Thomas</dc:creator>
                <dc:source>Herpesviridae 2012, null:4</dc:source>
        <dc:date>2012-03-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-3-4</dc:identifier>
                                <prism:require>/content/figures/2042-4280-3-4-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2012-03-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/2/1/7">
        <title>Detection of human cytomegalovirus in motile spermatozoa and spermatogenic cells in testis organotypic culture</title>
        <description>Background:
The presence of human cytomegalovirus (HCMV) in male genital tract suggests its vertical transmission with spermatozoa and the development of a potentially dangerous fetal infection. The objective of the present study was to evaluate the possibility of intracellular HCMV localization in male germ cells and to examine the effect of the virus on human spermatogenesis.
Methods:
Semen samples from 91 infertile and 47 fertile men were analyzed. HCMV was detected by real time PCR, rapid culture method and PCR in situ. Human testis organotypic culture and quantitative karyological analysis were used to investigate viral effects on spermatogenesis. Localization of HCMV in immature germ cells and spermatozoa was studied by immunostaining with monoclonal antibodies and ultrastructural analysis of infected organotypic culture.
Results:
Viral DNA was detected in 12.3% samples of motile spermatozoa, while infectious activity only in 2.9% infertile and fertile men without statistically significant intergroup difference. According to PCR in situ, the mean percentage of infected cell in both groups was 1.5% (0.25%-15%), which can serve as a criterion for evaluating the risk of HCMV transmission. In HCMV-infected organotypic culture viral antigens were identified in spermatides on day 4, in spermatogonia and spermatocytes on day 8, and in spermatozoa on day 14. Empty and full capsides and virions were visualized in germ cells by electron microscopy. The number of cells before introduction in culture was taken for 100%. On day 14 infected culture contained 36.8% spermatogonia, 18.7% spermatocytes, 27.6% round spermatides and 42.5% elongated spermatides; in comparison with 82.2%, 51.5%, 70.4% and 65.7% in uninfected culture, respectively (all p &lt; 0.05). There were no changes in the number and viability of spermatozoa.
Conclusions:
HCMV was detected in male germ cells, both in sperm samples and in testis organotypic culture. The virus may infect immature germ cells which develop to mature HCMV-carrying spermatozoa. A considerable decrease in the number of immature germ cells indicates that HCMV produces a direct gametotoxic effect and can contribute to male infertility.</description>
        <link>http://www.herpesviridae.org/content/2/1/7</link>
                <dc:creator>Victor Naumenko</dc:creator>
                <dc:creator>Yurii Tyulenev</dc:creator>
                <dc:creator>Sergei Yakovenko</dc:creator>
                <dc:creator>Lubov' Kurilo</dc:creator>
                <dc:creator>Ludmila Shileyko</dc:creator>
                <dc:creator>Aleksander Segal</dc:creator>
                <dc:creator>Larisa Zavalishina</dc:creator>
                <dc:creator>Regina Klimova</dc:creator>
                <dc:creator>Anton Tsibizov</dc:creator>
                <dc:creator>Sergei Alkhovskii</dc:creator>
                <dc:creator>Alla Kushch</dc:creator>
                <dc:source>Herpesviridae 2011, null:7</dc:source>
        <dc:date>2011-06-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-2-7</dc:identifier>
                                <prism:require>/content/figures/2042-4280-2-7-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2011-06-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/1/1/8">
        <title>Detection of human cytomegalovirus in normal and neoplastic breast epithelium </title>
        <description>IntroductionHuman cytomegalovirus (HCMV) establishes a persistent life-long infection, and can cause severe pathology in the fetus and the immunocompromised host
1
. Breast milk is the primary route of transmission in humans worldwide, and breast epithelium is thus a likely site of persistent infection and/or reactivation, though this phenomenon has not previously been demonstrated. Increasing evidence indicates HCMV infection can modulate signaling pathways associated with oncogenesis. We hypothesized that persistent HCMV infection occurs in normal adult breast epithelium and that persistent viral expression might be associated with normal and neoplastic ductal epithelium.
Methods:
Surgical biopsy specimens of normal breast (n = 38) breast carcinoma (n = 39) and paired normal breast from breast cancer patients (n = 21) were obtained. Specimens were evaluated by immunohistochemistry, in situ hybridization, PCR and DNA sequencing for evidence of HCMV antigens and nucleic acids.
Results:
We detected HCMV expression specifically in glandular epithelium in 17/27 (63%) of normal adult breast cases evaluated. In contrast, HCMV expression was evident in the neoplastic epithelium of 31/32 (97%) patients with ductal carcinoma in situ (DCIS) and infiltrating ductal carcinoma (IDC) cases evaluated (p = 0.0009).
Conclusions:
These findings are the first to demonstrate that persistent HCMV infection occurs in breast epithelium in a significant percentage of normal adult females. HCMV expression was also evident in neoplastic breast epithelium in a high percentage of normal and neoplastic breast tissues obtained from breast cancer patients, raising the possibility that viral infection may be involved in the neoplastic process.</description>
        <link>http://www.herpesviridae.org/content/1/1/8</link>
                <dc:creator>Lualhati Harkins</dc:creator>
                <dc:creator>Lisa Matlaf</dc:creator>
                <dc:creator>Liliana Soroceanu</dc:creator>
                <dc:creator>Katrin Klemm</dc:creator>
                <dc:creator>William Britt</dc:creator>
                <dc:creator>Wenquan Wang</dc:creator>
                <dc:creator>Kirby Bland</dc:creator>
                <dc:creator>Charles Cobbs</dc:creator>
                <dc:source>Herpesviridae 2010, null:8</dc:source>
        <dc:date>2010-12-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-1-8</dc:identifier>
                                <prism:require>/content/figures/2042-4280-1-8-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2010-12-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/1/1/6">
        <title>Epstein-Barr virus genetics: talking about the BAC generation</title>
        <description>Genetic mutant organisms pervade all areas of Biology. Early on, herpesviruses (HV) were found to be amenable to genetic analysis using homologous recombination techniques in eukaryotic cells. More recently, HV genomes cloned onto a bacterial artificial chromosome (BAC) have become available. HV BACs can be easily modified in E.coli and reintroduced in eukaryotic cells to produce infectious viruses. Mutants derived from HV BACs have been used both to understand the functions of all types of genetic elements present on the virus genome, but also to generate mutants with potentially medically relevant properties such as preventative vaccines. Here we retrace the development of the BAC technology applied to the Epstein-Barr virus (EBV) and review the strategies available for the construction of mutants. We expand on the appropriate controls required for proper use of the EBV BACs, and on the technical hurdles researchers face in working with these recombinants. We then discuss how further technological developments might successfully overcome these difficulties. Finally, we catalog the EBV BAC mutants that are currently available and illustrate their contributions to the field using a few representative examples.</description>
        <link>http://www.herpesviridae.org/content/1/1/6</link>
                <dc:creator>Regina Feederle</dc:creator>
                <dc:creator>Emmalene Bartlett</dc:creator>
                <dc:creator>Henri-Jacques Delecluse</dc:creator>
                <dc:source>Herpesviridae 2010, null:6</dc:source>
        <dc:date>2010-12-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-1-6</dc:identifier>
                                <prism:require>/content/figures/2042-4280-1-6-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2010-12-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/2/1/8">
        <title>Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations </title>
        <description>Epstein-Barr virus (EBV) is a highly successful herpesvirus, colonizing more than 90% of the adult human population worldwide, although it is also associated with various malignant diseases. Primary infection is usually clinically silent, and subsequent establishment of latency in the memory B lymphocyte compartment allows persistence of the virus in the infected host for life. EBV is so markedly B-lymphotropic when exposed to human lymphocytes in vitro that the association of EBV with rare but distinct types of T and NK cell lymphoproliferations was quite unexpected. Whilst relatively rare, these EBV-associated T and NK lymphoproliferations can be therapeutically challenging and prognosis for the majority of patients is dismal. In this review, we summarize the current knowledge on the role of EBV in the pathogenesis of these tumours, and the implications for treatment.</description>
        <link>http://www.herpesviridae.org/content/2/1/8</link>
                <dc:creator>Christopher Fox</dc:creator>
                <dc:creator>Claire Shannon-Lowe</dc:creator>
                <dc:creator>Martin Rowe</dc:creator>
                <dc:source>Herpesviridae 2011, null:8</dc:source>
        <dc:date>2011-09-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-2-8</dc:identifier>
                                <prism:require>/content/figures/2042-4280-2-8-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2011-09-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/3/1/1">
        <title>Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2</title>
        <description>Background:
X-linked lymphoproliferative syndrome (XLP) is a rare inherited immunodeficiency by an extreme vulnerability to Epstein-Barr virus (EBV) infection, frequently resulting in hemophagocytic lymphohistiocytosis (HLH). XLP are now divided into type 1 (XLP-1) and type 2 (XLP-2), which are caused by mutations of SH2D1A/SLAM-associated protein (SAP) and X-linked inhibitor of apoptosis protein (XIAP) genes, respectively. The diagnosis of XLP in individuals with EBV-associated HLH (EBV-HLH) is generally difficult because they show basically similar symptoms to sporadic EBV-HLH. Although EBV-infected cells in sporadic EBV-HLH are known to be mainly in CD8+ T cells, the cell-type of EBV-infected cells in EBV-HLH seen in XLP patients remains undetermined.
Methods:
EBV-infected cells in two patients (XLP-1 and XLP-2) presenting EBV-HLH were evaluated by in EBER-1 in situ hybridization or quantitative PCR methods.
Results:
Both XLP patients showed that the dominant population of EBV-infected cells was CD19+ B cells, whereas EBV-infected CD8+ T cells were very few.
Conclusions:
In XLP-related EBV-HLH, EBV-infected cells appear to be predominantly B cells. B cell directed therapy such as rituximab may be a valuable option in the treatment of EBV-HLH in XLP patients.</description>
        <link>http://www.herpesviridae.org/content/3/1/1</link>
                <dc:creator>Xi Yang</dc:creator>
                <dc:creator>Taizo Wada</dc:creator>
                <dc:creator>Ken-ichi Imadome</dc:creator>
                <dc:creator>Naonori Nishida</dc:creator>
                <dc:creator>Takeo Mukai</dc:creator>
                <dc:creator>Mitsuhiro Fujiwara</dc:creator>
                <dc:creator>Haruka Kawashima</dc:creator>
                <dc:creator>Fumiyo Kato</dc:creator>
                <dc:creator>Shigeyoshi Fujiwara</dc:creator>
                <dc:creator>Akihiro Yachie</dc:creator>
                <dc:creator>Xiaodong Zhao</dc:creator>
                <dc:creator>Toshio Miyawaki</dc:creator>
                <dc:creator>Hirokazu Kanegane</dc:creator>
                <dc:source>Herpesviridae 2012, null:1</dc:source>
        <dc:date>2012-02-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-3-1</dc:identifier>
                                <prism:require>/content/figures/2042-4280-3-1-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2012-02-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/2/1/10">
        <title>Evolving evidence implicates cytomegalovirus as a promoter of malignant glioma pathogenesis </title>
        <description>Human cytomegalovirus (HCMV) was first reported to be strongly associated with human malignant gliomas in 2002. HCMV is a herpesvirus that causes congenital brain infection and multi-organ disease in immumocompromised individuals. Malignant gliomas are the most common and aggressive adult brain tumors and glioblastoma multiforme (GBM), the highest grade glioma, is associated with a life expectancy of less than two years. HCMV gene products encode for multiple proteins that can promote the various signaling pathways critical to tumor growth, including those involved in mitogenesis, mutagenesis, apoptosis, inflammation, angiogenesis, invasion and immuno-evasion. Several groups have now demonstrated that human malignant gliomas are universally infected with HCMV and express gene products that can promote key signaling pathways in glioma pathogenesis. In this review I discuss specific HCMV gene products that we and others have recently found to be expressed in GBM in vivo, including the HCMV IE1, US28, gB and IL-10 proteins. The roles these HCMV gene products play in dysregulating key pathways in glioma biology, including the PDGFR, AKT, STAT3, and monocyte/microglia function are discussed. Finally, I review emerging human clinical trials for GBM based on anti-HCMV strategies.</description>
        <link>http://www.herpesviridae.org/content/2/1/10</link>
                <dc:creator>Charles Cobbs</dc:creator>
                <dc:source>Herpesviridae 2011, null:10</dc:source>
        <dc:date>2011-10-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-2-10</dc:identifier>
                                <prism:require>/content/figures/2042-4280-2-10-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2011-10-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

